TY - JOUR
T1 - The current role of nuclear medicine in breast cancer
AU - Vaz, Sofia C.
AU - Oliveira, Carla
AU - Teixeira, Ricardo
AU - Pereira Arias-Bouda, Lenka M.
AU - Cardoso, Maria João
AU - DE GEUS-OEI, Lioe Fee
N1 - Publisher Copyright:
© 2023 The Authors.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Breast cancer is the most common cancer in females worldwide. Nuclear medicine plays an important role in patient management, not only in initial staging, but also during follow-up. Radiopharmaceuticals to study breast cancer have been used for over 50 years, and several of these are still used in clinical practice, according to the most recent guideline recommendations. In this critical review, an overview of nuclear medicine procedures used during the last decades is presented. Current clinical indications of each of the conventional nuclear medicine and PET/CT examinations are the focus of this review, and are objectively provided. Radionuclide therapies are also referred, mainly summarising the methods to palliate metastatic bone pain. Finally, recent developments and future perspectives in the field of nuclear medicine are discussed. In this context, the promising potential of new radiopharmaceuticals not only for diagnosis, but also for therapy, and the use of quantitative imaging features as potential biomarkers, are addressed. Despite the long way nuclear medicine has gone through, it looks like it will continue to benefit clinical practice, paving the way to improve healthcare provided to patients with breast cancer.
AB - Breast cancer is the most common cancer in females worldwide. Nuclear medicine plays an important role in patient management, not only in initial staging, but also during follow-up. Radiopharmaceuticals to study breast cancer have been used for over 50 years, and several of these are still used in clinical practice, according to the most recent guideline recommendations. In this critical review, an overview of nuclear medicine procedures used during the last decades is presented. Current clinical indications of each of the conventional nuclear medicine and PET/CT examinations are the focus of this review, and are objectively provided. Radionuclide therapies are also referred, mainly summarising the methods to palliate metastatic bone pain. Finally, recent developments and future perspectives in the field of nuclear medicine are discussed. In this context, the promising potential of new radiopharmaceuticals not only for diagnosis, but also for therapy, and the use of quantitative imaging features as potential biomarkers, are addressed. Despite the long way nuclear medicine has gone through, it looks like it will continue to benefit clinical practice, paving the way to improve healthcare provided to patients with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85168315969&partnerID=8YFLogxK
U2 - 10.1259/bjr.20221153
DO - 10.1259/bjr.20221153
M3 - Review article
C2 - 37097285
AN - SCOPUS:85168315969
SN - 0007-1285
VL - 96
JO - British journal of radiology
JF - British journal of radiology
IS - 1149
M1 - 20221153
ER -